JP2020531514A5 - - Google Patents

Download PDF

Info

Publication number
JP2020531514A5
JP2020531514A5 JP2020511214A JP2020511214A JP2020531514A5 JP 2020531514 A5 JP2020531514 A5 JP 2020531514A5 JP 2020511214 A JP2020511214 A JP 2020511214A JP 2020511214 A JP2020511214 A JP 2020511214A JP 2020531514 A5 JP2020531514 A5 JP 2020531514A5
Authority
JP
Japan
Prior art keywords
receptor
rage
modulator according
modulator
cytoplasmic tail
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020511214A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531514A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2018/050883 external-priority patent/WO2019036753A1/en
Publication of JP2020531514A publication Critical patent/JP2020531514A/ja
Publication of JP2020531514A5 publication Critical patent/JP2020531514A5/ja
Priority to JP2023121818A priority Critical patent/JP2023156353A/ja
Priority to JP2025227130A priority patent/JP2026062654A/ja
Pending legal-status Critical Current

Links

JP2020511214A 2017-08-22 2018-08-21 終末糖化産物受容体（ｒａｇｅ）の活性化のスクリーニングアッセイ、モジュレーター及び調節 Pending JP2020531514A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023121818A JP2023156353A (ja) 2017-08-22 2023-07-26 終末糖化産物受容体（ｒａｇｅ）の活性化のスクリーニングアッセイ、モジュレーター及び調節
JP2025227130A JP2026062654A (ja) 2017-08-22 2025-12-03 終末糖化産物受容体（ｒａｇｅ）の活性化のスクリーニングアッセイ、モジュレーター及び調節

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2017903381 2017-08-22
AU2017903381A AU2017903381A0 (en) 2017-08-22 Screening Assays, Modulators and Modulation of Activation of Receptor For Advanced Glycation End-Products (RAGE)
AU2018902298 2018-06-26
AU2018902298A AU2018902298A0 (en) 2018-06-26 Screening Assays, Modulators and Modulation of Activation of Receptor for Advanced Glycation End-Products (RAGE)
PCT/AU2018/050883 WO2019036753A1 (en) 2017-08-22 2018-08-21 SCREENING TESTS, MODULATORS AND MODULATION OF RECEIVER ACTIVATION FOR ADVANCED GLYCATION TERMINAL PRODUCTS (RAGE)

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2023121818A Division JP2023156353A (ja) 2017-08-22 2023-07-26 終末糖化産物受容体（ｒａｇｅ）の活性化のスクリーニングアッセイ、モジュレーター及び調節
JP2025227130A Division JP2026062654A (ja) 2017-08-22 2025-12-03 終末糖化産物受容体（ｒａｇｅ）の活性化のスクリーニングアッセイ、モジュレーター及び調節

Publications (2)

Publication Number Publication Date
JP2020531514A JP2020531514A (ja) 2020-11-05
JP2020531514A5 true JP2020531514A5 (https=) 2021-09-30

Family

ID=65438276

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020511214A Pending JP2020531514A (ja) 2017-08-22 2018-08-21 終末糖化産物受容体（ｒａｇｅ）の活性化のスクリーニングアッセイ、モジュレーター及び調節
JP2023121818A Pending JP2023156353A (ja) 2017-08-22 2023-07-26 終末糖化産物受容体（ｒａｇｅ）の活性化のスクリーニングアッセイ、モジュレーター及び調節
JP2025227130A Pending JP2026062654A (ja) 2017-08-22 2025-12-03 終末糖化産物受容体（ｒａｇｅ）の活性化のスクリーニングアッセイ、モジュレーター及び調節

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023121818A Pending JP2023156353A (ja) 2017-08-22 2023-07-26 終末糖化産物受容体（ｒａｇｅ）の活性化のスクリーニングアッセイ、モジュレーター及び調節
JP2025227130A Pending JP2026062654A (ja) 2017-08-22 2025-12-03 終末糖化産物受容体（ｒａｇｅ）の活性化のスクリーニングアッセイ、モジュレーター及び調節

Country Status (7)

Country Link
US (2) US12060408B2 (https=)
EP (1) EP3672982A4 (https=)
JP (3) JP2020531514A (https=)
CN (2) CN120607606A (https=)
AU (1) AU2018322482B2 (https=)
CA (1) CA3109871A1 (https=)
WO (1) WO2019036753A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020531514A (ja) * 2017-08-22 2020-11-05 モナシュ・ユニヴァーシティ 終末糖化産物受容体（ｒａｇｅ）の活性化のスクリーニングアッセイ、モジュレーター及び調節
KR102203850B1 (ko) * 2019-04-09 2021-01-18 사회복지법인 삼성생명공익재단 신경교종의 진단 또는 예후 예측용 조성물 및 이에 관한 정보를 제공하는 방법
CN116249787A (zh) 2020-06-22 2023-06-09 雷杰纳荣制药公司 用g蛋白偶联受体75(gpr75)抑制剂治疗肥胖症
WO2022150709A1 (en) * 2021-01-11 2022-07-14 President And Fellows Of Harvard College Compositions and methods for treating viral infection
CN113293212A (zh) * 2021-06-17 2021-08-24 深圳华因康基因科技有限公司 一种检测神经母细胞瘤复发转移基因fzd2扩增的引物探针及其应用
CN113789379B (zh) * 2021-08-30 2022-08-23 远见生物科技（上海）有限公司 一种检测前列腺癌的诊断试剂盒及其检测方法与应用
JP2023084477A (ja) * 2021-12-07 2023-06-19 花王株式会社 硫黄化合物を原因とするにおいの抑制剤の評価及び／又は選択方法
KR20230147988A (ko) * 2022-04-15 2023-10-24 아주대학교산학협력단 Rage 길항제 및 age 소거제를 포함하는 당뇨성 뇌졸중 예방 또는 치료용 약학적 조성물
WO2024044659A1 (en) * 2022-08-24 2024-02-29 Tectonic Therapeutic, Inc. Constitutively active g protein-coupled receptor compositions and methods of use thereof
CN118777620A (zh) * 2023-04-07 2024-10-15 浙江友宁生物医药科技有限公司 Gpr139受体激活检测方法、生理功能评价方法及应用
CN116410335B (zh) * 2023-04-24 2024-08-13 徐州医科大学 一种多肽tat-mrgprx1c及其应用
CN118755834B (zh) * 2024-07-15 2025-11-18 河北医科大学第四医院（河北省肿瘤医院） 胃癌复发预测模型
CN119901926A (zh) * 2025-03-31 2025-04-29 浙江省立同德医院(浙江省精神卫生研究院) 一种基于rage过表达和spr技术的rage靶向药物筛选方法
CN121695261B (zh) * 2026-02-11 2026-04-17 湖南启元生物科技有限公司 一种蛋白组合物及其制备方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5004687A (en) 1985-05-21 1991-04-02 University Of Georgia Research Foundation, Inc. Insect virus vector with broadened host range
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US5273876A (en) 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
WO1990009441A1 (en) 1989-02-01 1990-08-23 The General Hospital Corporation Herpes simplex virus type i expression vector
GB8923123D0 (en) 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
EP1285967A3 (en) 1990-09-21 2005-03-02 Chiron Corporation Human retroviral packaging cell line
DE69131908T3 (de) 1991-02-19 2008-04-03 Oxford Biomedica (Uk) Ltd. Viruspartikel mit veraendertem wirtspektrum
GB9105383D0 (en) 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
DE69326967T2 (de) 1992-01-17 2000-06-15 Lakowicz, Joseph R. Phasenmodulationsenergieübertragungsfluoroimmunassay
AU3972893A (en) 1992-04-03 1993-11-08 Baylor College Of Medicine Gene therapy using the intestine
US6130074A (en) 1992-06-01 2000-10-10 American Cyanamid Company Five Giralda Farms Recombinant insect virus with reduced capacity for host-to-host transmission in the environment and methods to produce said virus
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
JP3147514B2 (ja) 1992-07-08 2001-03-19 住友電装株式会社 電線送給装置
WO1994012629A1 (en) 1992-12-02 1994-06-09 Baylor College Of Medicine Episomal vectors for gene therapy
WO1994023048A2 (en) 1993-04-06 1994-10-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gibbon ape leukemia virus-based retroviral vectors
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
US6120764A (en) 1993-06-24 2000-09-19 Advec, Inc. Adenoviruses for control of gene expression
US6140087A (en) 1993-06-24 2000-10-31 Advec, Inc. Adenovirus vectors for gene therapy
EP0728202A4 (en) 1993-11-12 1997-04-23 Univ Case Western Reserve EPISOMIC EXPRESSION VECTOR FOR HUMAN GENE THERAPY
US5731172A (en) 1994-03-09 1998-03-24 Sumitomo Pharmaceuticals Company, Ltd. Recombinant adenovirus and process for producing the same
ES2267101T3 (es) 1994-04-29 2007-03-01 PHARMACIA & UPJOHN COMPANY LLC Vacuna contra virus de inmunodeficiencia felina.
US5604090A (en) 1994-06-06 1997-02-18 Fred Hutchinson Cancer Research Center Method for increasing transduction of cells by adeno-associated virus vectors
US5662897A (en) 1994-07-27 1997-09-02 U. Of Ga Research Foundation Insect viruses, sequences, insecticidal compositions and methods of use
US5693508A (en) 1994-11-08 1997-12-02 Chang; Lung-Ji Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats
JP3770333B2 (ja) 1995-03-15 2006-04-26 大日本住友製薬株式会社 組換えｄｎａウイルスおよびその製造方法
GB9506782D0 (en) 1995-04-01 1995-05-24 British Biotech Pharm Retroviral vectors
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
AU722196B2 (en) 1995-08-30 2000-07-27 Genzyme Corporation Chromatographic purification of adenovirus and AAV
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6020192A (en) 1996-01-18 2000-02-01 University Of Florida Humanized green fluorescent protein genes and methods
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
JP2000506727A (ja) 1996-03-05 2000-06-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 組換え生ネコ免疫不全ウイルスおよびプロウイルスｄｎａワクチン
US5952221A (en) 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence
US5891646A (en) 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6143565A (en) 1997-08-22 2000-11-07 The United States Of America As Represented By The Secretary Of Agriculture Stable insect virus-cell expression system
US6893827B1 (en) 2000-02-07 2005-05-17 Applera Corporation Receptor function assay for G-protein coupled receptors and orphan receptors by reporter enzyme mutant complementation
NZ526720A (en) 2000-12-28 2007-11-30 Altus Pharmaceuticals Inc Crystallisation of whole antibodies or fragments thereof, on a large scale and a process allowing an alternative route for delivery of therapeutic antibodies
WO2003008446A1 (fr) 2001-07-19 2003-01-30 Mitsubishi Pharma Corporation Polypeptides se rapportant au transfert de signaux de recepteur de produits terminaux a glycation avancee
JP4734498B2 (ja) 2003-07-09 2011-07-27 ライフ テクノロジーズ コーポレイション タンパク質−タンパク質相互作用を解析する方法
US7488583B2 (en) 2003-09-25 2009-02-10 Odyssey Thera, Inc. Fragment complementation assays for G-protein-coupled receptors and their signaling pathways
JP5188804B2 (ja) 2004-08-03 2013-04-24 トランステック ファーマ，インコーポレイティド Ｒａｇｅ融合タンパク質及びその使用方法
MX2007011411A (es) * 2005-03-17 2007-11-13 Univ Columbia Interaccion rage/diaphanous y composiciones relacionadas y metodos.
KR100859972B1 (ko) 2006-02-20 2008-09-25 이화여자대학교 산학협력단 막투과 단백질 도메인 펩타이드
MX2008012023A (es) 2006-03-21 2008-10-01 Wyeth Corp Metodos para prevenir y tratar enfermedades amiloidogenicas.
DK2080012T3 (da) 2006-11-10 2013-06-17 Dimerix Bioscience Pty Ltd Fremgangsmåder til analyse af testforbindelser på forbundne receptorer.
US20100249038A1 (en) 2007-06-12 2010-09-30 Board Of Regents, University Of Texas System Antagonists of the receptor for advanced glycation end-products (rage)
US8101373B2 (en) 2007-10-12 2012-01-24 Discoverx Corporation β-galactosidase donor fragments
WO2012109569A1 (en) 2011-02-11 2012-08-16 The Trustees Of Columbia University In The City Of New York The receptor for advanced glycation endproducts (rage) is a receptor for lysophosphatidic acid (lpa)
AU2012260434A1 (en) 2011-05-23 2013-10-31 Phylogica Limited Method of determining, identifying or isolating cell-penetrating peptides
JP2014527180A (ja) 2011-09-14 2014-10-09 アベテルノ リミテッド 細胞内細胞選別
JP2020531514A (ja) * 2017-08-22 2020-11-05 モナシュ・ユニヴァーシティ 終末糖化産物受容体（ｒａｇｅ）の活性化のスクリーニングアッセイ、モジュレーター及び調節

Similar Documents

Publication Publication Date Title
JP2020531514A5 (https=)
Toro et al. MaxiK channel and cell signalling
JP7212009B2 (ja) Ｃｘｃｒ４結合分子
EP2970415B1 (en) Apelin fusion proteins and uses thereof
CA2586344C (en) G protein coupled receptor agonists and antagonists and methods of use
AU2006212813B2 (en) Compositions and methods related to soluble G-protein coupled receptors (sGPCRs)
JP2024010090A (ja) リラキシン融合ポリペプチドおよびその使用
Kolakowski Jr et al. Probing the “Message: Address” Sites for Chemoattractant Binding to the C5a Receptor: MUTAGENESIS OF HYDROPHILIC AND PROLINE RESIDUES WITHIN THE TRANSMEMBRANE SEGMENTS
Lin et al. Comparison of the peptide structural requirements for high affinity interaction with bombesin receptors
CA2534748C (en) Relaxin superfamily peptide analogues
CN114591415B (zh) Glp-1/gcg双受体激动剂多肽及其融合蛋白
Fan et al. Molecular mechanism and structural basis of interactions of dipeptidyl peptidase IV with adenosine deaminase and human immunodeficiency virus type-1 transcription transactivator
US20120214744A1 (en) Polypeptides and nucleic acids for treating erbb2-dependent cancers
Lin et al. GPS proteolytic cleavage of adhesion-GPCRs
JP2011526491A (ja) インスリン融合ポリペプチド
Bermak et al. Accessory proteins in the biogenesis of G protein-coupled receptors
Schneider et al. Histamine H4 receptor–RGS fusion proteins expressed in Sf9 insect cells: A sensitive and reliable approach for the functional characterization of histamine H4 receptor ligands
EP1292677A2 (en) Human hm74-like g protein coupled receptor
US20080206231A1 (en) Compositions and Methods for Treating Disease
Zaidi et al. Molecular and clinical pharmacology of calcitonin
WO2020118363A1 (en) Screening assays, modulators and modulation of intracellular signalling mediated by immunoglobulin superfamily cell adhesion molecules
Li et al. Molecular cloning and functional characterization of a type-I neurotensin receptor (NTR) and a novel NTR from the bullfrog brain
WO2022140852A1 (en) Stim proteins couple nmda receptors to pannexin 1 activation
Lallement et al. Cholecystokinin and gastrin are not equally sensitive to GTPγS at CCKB receptors: importance of the sulphated tyrosine
Tomasovic et al. Role of Cbl-associated protein/ponsin in receptor tyrosine kinase signaling and cell adhesion